NAME: DATE: COURSE LOCATION: Contact medical control Report assessment findings including signs and symptoms of chest pain as well as medications patient is currently taking Report prior interventions Request implementation of nitroglycerine protocol Confirm orders from medical control Explain procedure and solicit patient consent Check expiration date Confirm right medication, right patient, right route Rule out allergies Confirm dosage 0.4 mg nitroglycerine Instruct patient to lift tongue Place tablet or apply spray sublingually Have the patient attempt to keep mouth closed until medication is dissolved absorbed Continue to monitor patient status blood pressure particularly important ; Continue oxygen therapy Repeat dosage per medical direction, if requested Document administration data and time o Time, name, dose, route of medication o Patient's tolerance of procedure o Name of medical control physician authorizing administration o Name of EMT administering medication Reevaluate patient response to medication administration EVALUATOR: DATE.
A blood transfusion is required if: Hb is 4 and the child has respiratory distress. In severe malnutrition, the transfusion must be slower and of smaller volume than for a well-nourished child. Give: whole blood, 10 ml kg slowly over 3 hours furosemide, 1 mg kg IV at the start of the transfusion. If the child has signs of heart failure, give 10 ml kg packed cells because whole blood is likely to worsen this condition. Children with kwashiorkor may have redistribution of fluid leading to apparent low Hb which does not require transfusion. Monitor the pulse and breathing rates every 15 minutes during the transfusion. If either increases breathing by 5 breaths minute or pulse by 25 beats minute ; , transfuse more slowly and glyburide. Ndc list PRAVACHOL 10 MG TABLET PRAVACHOL 20 MG TABLET PRAVACHOL 20 MG TABLET PRAVACHOL 20 MG TABLET DILTIAZEM 30 MG TABLET DILTIAZEM 30 MG TABLET DILTIAZEM 30 MG TABLET DILTIAZEM 30 MG TABLET BENZTROPINE MES 2 MG TABLET BENZTROPINE MES 2 MG TABLET HALOPERIDOL 5 MG TABLET HALOPERIDOL 5 MG TABLET ISOSORBIDE DN 5 MG TABLET KAOPECTATE SUSPENSION FUROSEMIDE 10 MG ML VIAL BENZTROPINE MES 1 MG TABLET BENZTROPINE MES 1 MG TABLET CHLORPROMAZINE 50 MG TABLET CHLORPROMAZINE 50 MG TABLET FLUPHENAZINE 5 MG TABLET HALOPERIDOL 10 MG TABLET HEMORRHOIDAL OINTMENT HEMORRHOIDAL OINTMENT ANUSOL OINTMENT FOLIC ACID 1 MG TABLET FOLIC ACID 1 MG TABLET FOLIC ACID 1 MG TABLET SEASONALE 0.15 0.03 MG TAB DOXEPIN 10 MG CAPSULE DOXEPIN 10 MG CAPSULE DOXEPIN 10 MG CAPSULE LEFLUNOMIDE 20 MG TABLET DIAZEPAM 5 MG ML VIAL DIAZEPAM 5 MG ML VIAL DILACOR XR 180 MG CAPSULE SA DILACOR XR 180 MG CAPSULE SA LOXAPINE SUCCINATE 10 MG CAP APLISOL 5T UNITS 0.1 ML VIAL LIDOCAINE HCL 1% VIAL LIDOCAINE HCL 1% VIAL COZAAR 100 MG TABLET COLACE 100 MG CAPSULE BIAXIN 500 MG TABLET BIAXIN 500 MG TABLET BIAXIN 500 MG TABLET BIAXIN 500 MG TABLET BIAXIN 500 MG TABLET TRIHEXYPHENIDYL 2 MG TABLET TRIHEXYPHENIDYL 2 MG TABLET THIOTHIXENE 2 MG CAPSULE MILK OF MAGNESIA SUSPENSION MILK OF MAGNESIA SUSPENSION Page 546. Implementation of a fluid-restrictive strategy reduces the duration of mechanical ventilation and may affect survival of patients with pulmonary edema 9 ; . Physiology also supports restoration of the colloid osmotic pressure COP ; gradient to prevent edema formation, at least when permitted by capillary permeability 5 ; . Administration of colloids to patients with ALI ARDS does not worsen pulmonary edema when hydrostatic pressures remain unchanged 10 ; . Expanding evidence associates elevated hydrostatic pressures, fluid retention, and weight gain with mortality in ALI ARDS, yet there has never been a prospective, randomized trial of diuretic therapy in this patient population 11, 12 ; . Data from our previous clinical trial found significant benefits in oxygenation and systemic hemodynamics for patients with ALI ARDS treated with the combination of albumin and furosemide, in com1681 and hydrochlorothiazide. A b otic ABILIFY, -DISCMELT ACCOLATE ACCU-CHEK ACCU-CHEK SIMPLICITY ACCUPRIL ACCURETIC ACCUTANE ACEON acetaminophen w codeine acetaminophen w hydrocodone ACIPHEX ACLOVATE ACTIGALL ACTIQ ACTIVELLA ACTONEL ACTOPLUS MET ACTOS ACULAR PF acyclovir ADDERALL XR ADVAIR DISKUS ADVICOR AEROBID AEROBID-M AGENERASE AGGRENOX ALAMAST albuterol ALDARA ALESSE ALLEGRA ALLEGRA-D ALLERX TABLETS allopurinol ALOCRIL ALOMIDE ALORA ALPHAGAN P ALREX ALTACE ALTOPREV amantadine HCl AMARYL AMBIEN, -CR amcinonide AMERGE amiloride HCl HCTZ amiodarone HCl amnesteem amox tr potassium clavulanate amoxicillin amphetamine salt combo ANDRODERM ANDROGEL ANTARA ANZEMET apap cafffeine butalbital APIDRA APOKYN apri ARANESP ARICEPT ARIMIDEX ARMOUR THYROID ARTHROTEC 75 ASACOL ASCENSIA AUTODISC ASCENSIA ELITE ASMANEX aspirin caffeine butalbital ASTELIN ATACAND ATACAND HCT atenolol atenolol w chlorthalidone ATIVAN ATRIPLA ATROVENT INHALER ATROVENT NASAL SPRAY ATROVENT SOLUTION 7.1 5.8 15.1.4 AUGMENTIN all forms AVALIDE AVANDAMET AVANDARYL AVANDIA AVAPRO AVELOX ABC PACK AVINZA AVITA AVODART AVONEX AXERT AXID azathioprine AZELEX AZILECT azithromycin AZMACORT AZOPT baclofen BACTROBAN CREAM BACTROBAN OINTMENT BECONASE AQ benazepril BENICAR BENICAR HCT BENZACLIN BENZAMYCIN, -PAK benzonatate betamethasone dp 0.05% cream BETAPACE AF BETASERON BETIMOL BIAXIN BIAXIN XL bisoprolol fumarate bisoprolol fumarate HCTZ BONIVA brimonidine tartrate bromocriptine mesylate budeprion SR 150MG bumetanide bupropion HCl bupropion SR BUSPAR BYETTA CADUET camila CANASA CAPEX SHAMPOO captopril captopril HCTZ CARAFATE carbamazepine carbidopa levodopa CARDENE SR CARDIZEM CD LA CARDURA carisoprodol carteolol HCl cartia XT CASODEX CEDAX cefaclor cefaclor ER cefpodoxime cefprozil CEFTIN cefuroxime tablet CEFZIL CELEBREX CELEXA CELLCEPT CENESTIN cephalexin ciclopirox CILOXAN CIPRO HC CIPRO XR CIPRODEX CIPRODEX OTIC ciprofloxacin 0.3% ciprofloxacin HCl 2.1.5 4.5.6 8.1.3 citalopram claravis CLARINEX clarithromycin CLIMARA CLIMARA PRO clindamycin HCl clindamycin phosphate clobetasol propionate clonidine HCl clotrimazole betamethasone clozapine COGENTIN COLAZAL colchicine COLYTE WITH FLAVOR PACKETS COMBIPATCH COMBIVENT COMBIVIR COMTAN CONCERTA CONDYLOX GEL CONDYLOX TOPICAL SOLUTION COPAXONE COPEGUS COREG CORTIFOAM COSOPT COUMADIN COVERA-HS COZAAR CREON CRESTOR cromolyn sodium cryselle CYCLESSA cyclobenzaprine HCl cyclosporine CYMBALTA DARVOCET N-100 DDAVP DEMULEN 1 35 DEMULEN 1 50 DEPAKOTE all forms desipramine HCl desmopressin DESOGEN desoximetasone DETROL DETROL LA dexamethasone dexamethasone diclofenac sodium dicyclomine HCl DIDRONEL DIFFERIN diflorasone diacetate DIFLUCAN diflunisal digitek digoxin DILANTIN diltiazem ER diltiazem HCl diltiazem XR DIOVAN DIOVAN HCT DIPENTUM diphenoxylate w atropine dipyridamole DITROPAN XL DORYX DOVONEX doxazosin doxepin HCl doxycycline hyclate DURAPHEN II DYAZIDE DYNACIRC CR econazole nitrate EFFEXOR EFFEXOR XR 5.5.1.3 6.3 15.2.1 EFUDEX ELAVIL ELIDEL ELOCON EMADINE EMEND EMSAM EMTRIVA ENABLEX enalapril maleate enalapril maleate HCTZ ENBREL ENJUVIA EPIVIR EPIVIR HBV EPOGEN errin erythrocin stearate erythromycin erythromycin base erythromycin ethylsuccinate erythromycin w sulfisoxazole ESTRACE ESTRADERM estradiol estradiol transdermal patch ESTRASORB ESTRATEST ESTRATEST H.S. ESTROGEL estropipate ESTROSTEP FE ethosuximide etodolac EUFLEXXA EVISTA EXELDERM EXELON EXUBERA FAMVIR FAST TAKE felodipine ER FEMARA FEMHRT fenofibrate fentanyl oral transmucosal FENTORA fexofenadine FINACEA finasteride FIORICET FIORINAL flecainide acetate FLEXERIL FLOMAX FLONASE FLOVENT HFA FLOXIN OTIC fluconazole fludrocortisone acetate FLUMADINE fluorometholone fluoxetine HCl flurazepam HCl flutamide fluticasone nasal spray fluvoxamine maleate FML FORTE FOCALIN folic acid FORADIL FORTEO fortical nasal spray FOSAMAX FOSAMAX PLUS D fosinopril sodium fosinopril HCTZ FOSRENOL FREESTYLE FREESTYLE TEST STRIPS FROVA furosemide gabapentin GANTRISIN gemfibrozil GENOTROPIN GEODON. The increase in medical imaging sales was primarily the result of a 12% increase in sales of cardiolite to $86 million and hydrocodone.
Contraindications: 1. Hypovolemia 2. Pregnancy Adverse effects: 1. Hypotension 2. Transient hearing loss 3. Hypokalemia 40-80 mg slow IVP over 2-4 minutes Not recommended for prehospital use 5-10 minutes 2-3 hours Pregnancy Safety: Category C Rapid administration may cause permanent hearing loss If patient's blood pressure drops below 100 mmHg, discontinue furosemide administration.

The following table shows relative placement of this quarter's top ten drugs by number of prescriptions over the last seven fiscal quarters. Drug Lipitor 10 mg Norvasc 5 mg Prilosec 20 mg Celebrex 200 mg Xalatan 0.005% Fu5osemide 40 mg Lipitor 20 mg K-DUR 20meq Prevacid 30 mg Glucophage 500 mg Norvasc 10 mg Vioxx 25 mg Furisemide 20 mg Humulin N 100 U ml Plavix 75 mg Toprol XL 50 mg Metoprolol Tartrate 50 mg Combivant 103-18 mcg Fosamax 70 mg Fosamax 10 mg Miacalcin 200u dose Zoloft 50 mg Paxil 20 mg Premarin 0.625 mg Zestril 10 mg Lanoxin 0.125 mg Ambien 10 mg Zestril 20 mg Prozac 20 mg Ultram 50 mg Q4 1 2 3 SFY 2001 Q3 Q2 1 SFY 2000 Q3 1 2 BACKGROUND Pharmaceutical manufacturers are required to participate in the Manufacturer Rebate Program in order to have their pharmaceutical products covered by ConnPACE. The rebate is equivalent to the rebate supplied under Section 1927 of Title XIX of the Social Security Act. REBATE AMOUNT The amount of the rebate is the sum of the Basic Rebate Amounts of each drug product computed for each dosage form and strength of each prescription drug ; calculated by the manufacturer and supplied to the Health Care Financing Administration HCFA ; and applied as follows: 1 ; Multiply the total number of units paid under ConnPACE for the program participants during the quarter by 2 ; Basic Rebate Amount for the drug, plus when applicable 3 ; The Additional Rebate equal to the rebate amount calculated for Medicaid according to Section 1927 C ; 2 ; of the Social Security Act ; . The rebate must be paid quarterly and be based on quarterly utilization information sent by the Department to participating drug manufacturers. PARTICIPATION As of June 30, 2001, a total of 309 manufacturers were participating in the Rebate Program. The only drugs that continued to be covered without a Rebate Agreement with the manufacturers are: Dapsone prescribed for the treatment of Leprosy ; Mestinon prescribed for the treatment of Myasthenia Gravis ; Hexalen prescribed for the treatment of advanced ovarian cancer ; Benoquin prescribed for the treatment of malignant moles and tumors and hyzaar.

Rank 1 2 3 Drug Lipitor 10mg Norvasc 5mg Fosamax 70mg Lipitor 20mg Prevacid 30mg Celebrex 200mg Furos4mide 40mg Plavix 75mg Norvasc 10mg Toprol XL 50 mg Xalatan 0.005% Nexium 40mg Fursoemide 20mg Combivent 103-18MC Hydrochlorothiazide 25mg Metoprolol Tartrate 50mg Zocor 20mg Protonix 40mg Humulin N 100U ML Ambien 10mg Toprol XL 100mg Lipitor 40mg Vioxx 25mg Metoprolol Tartrate 50mg Atenolol 50mg Zithromax 250 mg Zoloft 50mg Cosopt 0.5-2% Neurotin 300 mg Atenolol 50 mg Total.
Criteria: inclusion criteria: - age 25-75 years - type 2 diabetes mellitus for less than or equal to 10 years - pre-screening hba1c 5 % - screening 110 mg dl exclusion criteria: - thiazolidinedione or sulfonylurea use in previous 30 days may undergo washout period of 30 days ; - known contraindications to use of thiazolidinedione or sulfonylurea - female patients must be postmenopausal, surgically sterile, or using adequate contraception - uncontrolled hyperlipidemia according to american heart association aha ; guidelines - subcutaneous insulin use - elevated liver enzymes 5 times the upper limit of the reference range ; - serum creatinine 160 mmol l - anemia hb - body mass index bmi ; 42 kg m2 - history of ketoacidosis - angina new york health academy class iii iv cardiac insufficiency - electrocardiographic evidence of marked left ventricular hypertrophy - uncontrolled hypertension according to aha guidelines - hemoglobinopathy locations and contacts st and ibuprofen.

Brain bulk may be treated to lower ICP with osmotherapy using mannitol 0.250.5 g kg every 4 hours ; and furossmide 10 mg every 28 hours ; . Alternating administering of these agents is routine, and they are administered as needed for ICP spikes. Serum osmolarity and sodium concentrations should be measured typically every 6 hours to target an osmolarity less than 310 mOsm L. Fluid management should aim to maintain euvolemia and normonatremia. Osmotherapy cannot be used to treat ICP if extremes of hypovolemia and hypernatremia are allowed to develop. Corticosteroids should not be used in treatment of ICH. Randomized trials show no efficacy in the treatment of ICH with corticosteroids [5860]. Hypocarbia 2535 mm Hg ; decreases the ICP by causing a cerebral vasoconstriction, and this is very effective in acute crises with waves of elevated ICP. Alternatively, extreme hyperventilation PCO2 ! 20 mm can exacerbate brain ischemia by decreasing cerebral blood flow. Hyperventilation also should not be used for a long period of time, because it becomes ineffective with metabolic adjustment to respiratory alkalosis. Further response to life-threatening ICP waves becomes ineffective after chronic hyperventilation, and patients become vulnerable to rebound increased ICP when restoring normocapnia. Sedation with neuromuscular paralysis can reduce elevated ICP by preventing agitation and straining. It also decreases brain metabolic demands. If the ICP remains high despite maximizing medical management discussed previously ; , induced barbiturate coma may be instituted with continuous EEG monitoring. A central line and arterial line are used and even a Swan-Ganz catheter and pressors, if needed, to maintain hemodynamic support during barbiturate-induced coma. Barbiturates can decrease ICP. Problem 1: Progressive CHF Restart digoxin 0.25 mg tab po qd for 5 days; reduce to 0.125 mg po qd; monitor digoxin levels in 1 to weeks; educate regarding signs of digoxin toxicity Discontinue torsemide; start fueosemide 40 mg tab po qd Start fosinopril 20 mg po qam; goal should be fosinopril 20-40 mg tab po qd; monitor serum K Refer for dietary counseling for weight loss; monitor daily weights; weight goal: see Problem 7 Obtain ejection fraction Problem 2: Ischemic cardiomyopathy S P MI Start enteric-coated aspirin 81 mg tab po qd Consider beta-blocking agent if patient remains tachycardic Treat with ACE inhibitor as discussed above Problem 3: Hypertension, uncontrolled; ran out of medications Monitor BP at home following changes suggested above; goal BP is 130 85 Discontinue NSAID use Monitor renal function over next 3 months Refer for dietary counseling as above Problem 4: Renal insufficiency secondary to NSAID use and hypertension Discontinue NSAID use Monitor renal function over next 3 months Problem 5: Osteoarthritis, stable Discontinue NSAID use; begin acetaminophen 650 mg tab po t.i.d. Encourage light exercise to maintain range of motion Begin strength-building exercise Dietary therapy with goal of weight reduction Problem 6: Polypharmacy and inability to afford medications Refer to pharmacist to help improve and monitor compliance Discontinue use of samples previously obtained Instruct BV to bring in all medications at next visit for review Refer for possible inclusion in manufacturers' patient assistance programs for obtaining prescription medications Problem 7: Obesity Refer for dietary counseling; initial goal weight is BMI of 30, long-term goal is 27 and imitrex and furosemide.

Heart failure clinic n 50 ; Age [years] Men Co-morbidities Ischaemic heart disease Myocardial infarction Arterial hypertension Diabetes Mellitus Chronic renal disease Hypercholesterolaemia Atrial fibrillation Stroke or transitory ischaemic attack Pulmonary rales Peripheral oedema Heart rate [beats min] Systolic blood pressure [mm Hg] Diastolic blood pressure [mm Hg] Blood urea nitrogen [mmol L] Creatinine [mol L] Glomerular filtration rate [ml min] * Glomerular filtration rate 60 ml min Sodium [mmol L] Haemoglobin [g L] Total cholesterol [mmol L] Left ventricular ejection fraction [%] NYHA class at baseline Length of stay [days] Pharmacolgical treatment at discharge ACE inhibitors Beta blockers Spironolactone Fu4osemide Digoxin Aspirin Warfarin Statins Nitrates Calcium antagonists 47 94% ; 20 40% ; 27 54% ; 42 84% ; 30 60% ; 13 26% ; 19 38% ; 14 28% ; 11 22% ; 6 12% ; 21 42% ; 14 28% ; 30 60% ; 13 26% ; 18 36% ; 20 40% ; 26 52% ; 3 6% ; 34 68% ; 42 84% ; 82 77, 90 ; 131 120, 144 ; 80 76, 84 ; 7.6 5.9, 9.1 ; 91 80, 109 ; 69 52, 84 ; 19 38% ; 139 138, 141 ; 142 134, 152 ; 5.1 4.3, 5.7 ; 40 35, 43 ; 3 ; 10 9, 56, ; 33 66!

ABSTRACT We sought to evaluate whether U.S. Pharmacopeia USP ; apparatus 3 can be used as an alternative to USP apparatus 2 for dissolution testing of immediate-release IR ; dosage forms. Highly soluble drugs, metoprolol and ranitidine, and poorly soluble drugs, acyclovir and furosemide, were chosen as model drugs. The dissolution profiles of both innovator and generic IR products were determined using USP apparatus 2 at 50 rpm and apparatus 3 at 5, 15, and 25 dips per minute dpm ; . The dissolution profiles from USP apparatus 3 were compared to those from USP apparatus 2 using the f 2 similarity test. The dissolution profile from USP apparatus 3 generally depends on the agitation rate, with a faster agitation rate producing a faster dissolution rate. It was found that USP apparatus 3 at the extreme low end of the possible agitation range, such as 5 dpm, gave hydrodynamic conditions equivalent to USP apparatus 2 at 50 rpm. With appropriate agitation rate, USP apparatus 3 can produce similar dissolution profiles to USP apparatus 2 or distinguish dissolution characteristics for the IR products of metoprolol, ranitidine, and acyclovir. Incomplete dissolution was observed for the furosemidde tablets using USP apparatus 3. Although it is primarily designed for the release testing of extended-release products, USP apparatus 3 may be used for the dissolution testing of IR products of highly soluble drugs, such as metoprolol and ranitidine, and some IR products of poorly soluble drugs, such as acyclovir. USP apparatus 3 offers the advantages of avoiding cone formation and mimicking the changes in physiochemical conditions and mechanical forces experienced by products in the gastrointestinal tract. 2 Leier CV, Dei Cas L, Metra M. Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. Heart J 1994; 128: 564574. Larsen FF. Haemodynamic effects of high or low doses of furosemide in acute myocardial infarction. Eur Heart J 1988; 9: 125131. Stampfer M, Epstein SE, Beiser GD, Braunwald E. Hemodynamic effects of diuresis at rest and during intense upright exercise in patients with impaired cardiac function. Circulation 1968; 37: 900911. Kramer BK, Schweda F, Kammerl M, Riegger GA. Diuretic therapy and diuretic resistance in cardiac failure. Nephrol Dial Transplant 1999; 14: 3942. Pickkers P, Dormans TP, Russel FG et al. Direct vascular effects of furosemide in humans. Circulation 1997; 96: 18471852. Dikshit K, Vyden JK, Forrester JS, Chatterjee K, Prakash R, Swan HJC. Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction. N Engl J Med 1973; 288: 10871090. Raftery EB. Haemodynamic effects of diuretics in heart failure. Br Heart J 1994; 72: 4447. Kelly DT. Vascular effects of diuretics in heart failure. Br Heart J 1994; 72: 4850. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine B, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Ann Intern Med 1985; 103: 16. Skott O, Briggs JP. Direct demonstration of macula densamediated renin secretion. Science 1987; 237: 16181620. Johnson W, Omland T, Hall C et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Coll Cardiol 2002; 39: 16231629. Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction SOLVD ; . J Coll Cardiol 2003; 42: 705708. Hampton JR. Results of clinical trials with diuretics in heart failure. Br Heart J 1994; 72: 6872. Odemuyiwa O, Gilmartin J, Kenny D, Hall RJ. Captopril and the diuretic requirements in moderate and severe chronic heart failure. Eur Heart J 1989; 10: 586590. Grinstead WC, Francis MJ, Marks GF, Tawa CB, Zoghbi WA, Young JB. Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy. J Cardiol 1994; 73: 881886. Walma EP, Hoes AW, van Dooren C, Prins A, van der Does E. Withdrawal of long-term diuretic medication in elderly patients: a double blind randomised trial. BMJ 1997; 315: 464468.

Years. When a person takes two or more ototoxic drugs at the same time, or one immediately following the other, there are two likely outcomes. The ototoxic effects of each drug can either be additive, or the ototoxic effects can be synergistic. In the first case, the total effect on the ears will be the sum of the effects of each drug as if they were taken separately. For example, if one ototoxic drug causes 2 "units" of damage and the second drug causes 3 "units" of damage, the resulting damage on the ear would be 5 "units" 2 + 3 This is the additive effect. However, with some drug combinations, using the same example above, the result is not 5 "units" of damage as you might expect, but a larger number--say 10 "units" of damage. This represents a synergistic effect. With synergistic effects, the resulting damage is always greater than the sum of the damage of each individual drug. To protect ears as much as possible, people should not take multiple ototoxic drugs at the same time, especially if they are known to have synergistic ototoxic effects. Researchers have discovered that the order a person takes certain ototoxic drugs can make an enormous difference as to whether they have much of a resulting hearing loss or not. With some drug combinations, if you take the drugs sequentially, and not simultaneously, you can avoid the synergistic effect. For example, in one medical treatment, doctors put their patients on two drugs, a Loop diuretic e.g., Furosemide ; and an Aminoglycoside antibiotic e.g., Tobramycin ; . If the patient completes the course of the Loop diuretic before he begins the Aminoglycoside antibiotic, the resulting hearing loss from these two drugs is additive. However, if the patient takes both drugs simultaneously or if the Aminoglycoside antibiotic is administered first, followed by the Loop diuretic--the two drugs act synergistically to significantly damage the patient's ears.25 Not only do certain ototoxic drugs react synergistically with each other, but they have another nefarious characteristic. Their ototoxic side effects can react synergistically with noise. Certain ototoxic drugs when taken "normally" can result in a certain degree of hearing loss. However, if they are being taken while the patient is exposed to loud noise, the noise combines synergistically with the ototoxic side effects of the drug to cause even greater hearing loss than might otherwise be expected. Some of the drugs that have this vicious effect include aspirin, 20 the anti-cancer drug Cisplatin, 22 the microbial antibiotic Chloramphenicol3 and Aminoglycoside antibiotics such as Gentamicin12 and Kanamycin.23 This same synergistic effect on hearing loss between the ototoxic side effects of certain. The U.S. Department of Justice "DOJ" ; disagreed with this interpretation of the governing law. Relying principally on two CMS Releases and a March, 2001 HHS-OIG audit report, federal prosecutors have taken the position that a manufacturer's sales of a drug to an HMO must be included in the computation of that manufacturer's Best Price, regardless of whether the HMO was repackaging or purchasing a private labeled version of the drug.9 Three settlements in this area illustrate the breadth and ultimate success of DOJ enforcement under this theory, for example, furosemide medicine.